Resolution of innate immune cells with proresolving lipid mediators in idiopathic pulmonary fibrosis
Journal of Leukocyte Biology · 2025
DOI: 10.1093/jleuko/qiaf100 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Leukocyte Biology, 2025. Verfasst von Yuet Ang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Immunity, Innate, Inflammation Mediators. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 179 Literaturangaben. Gefördert von: NUHS.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a progressive incurable lung disease characterized by chronic inflammation and fibrosis, with innate immune cells such as neutrophils and macrophages playing central roles in its pathogenesis. This review explores the involvement of these immune cells in the inflammatory process of IPF, focusing on their contribution to disrupted tissue repair and impaired resolution. The balance between host defense mechanisms, including leukocyte recruitment, and the release of proresolving mediators is crucial for maintaining healthy tissue function and returning to preinflammatory states. We highlight the importance of inflammation resolution to prevent an overactive immune response, which can lead to irreversible fibrosis. Specialized proresolving mediators, including lipoxins, resolvins, protectins, and maresins, are discussed in terms of their regulatory effects on neutrophils and macrophages in IPF. These mediators exhibit potent anti-inflammatory actions, which can modulate the immune response and promote the resolution of inflammation. Overall, this review underscores the significance of immune modulation in IPF, with a focus on the therapeutic potential of specialized proresolving mediators in controlling the inflammatory response and preventing fibrosis progression. Future research into the antifibrotic properties of SPMs and their impact on innate immune cell regulation holds promise for novel therapeutic strategies in IPF treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600.
- Immunology Translational Research Programme, Yong Loo Lin School of Medicine, Center for Life Sciences (CeLS), National University of Singapore, Singapore 117456.
- Immunology Programme and Singapore Lipidomics Incubator (SLING), Life Sciences Institute, Center for Life Sciences (CeLS), National University of Singapore, Singapore 117456.
- Drug Discovery and Optimization Platform, Yong Loo Lin School of Medicine, National University Health System, Singapore 117600.
- Adelaide Medical School, University of Adelaide, 4 North Terrace, Adelaide, SA 5000, Australia.
ORCID-Profile: Yuet Ang, Ashton J K Ng, Wupeng Liao, K Y Kevin Wong, W S Fred Wong, Hong Yong Peh
Förderung
- NUHS
Zitieren
APA
Ang, Y., Ng, A. J. K., Liao, W., Wong, K. Y. K., Wong, W. S. F., & Peh, H. Y. (2025). Resolution of innate immune cells with proresolving lipid mediators in idiopathic pulmonary fibrosis. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiaf100
Vancouver
Ang Y, Ng AJK, Liao W, Wong KYK, Wong WSF, Peh HY. Resolution of innate immune cells with proresolving lipid mediators in idiopathic pulmonary fibrosis. Journal of Leukocyte Biology. 2025. doi:10.1093/jleuko/qiaf100
BibTeX
@article{Ang2025,
author = {Ang, Yuet and Ng, Ashton J K and Liao, Wupeng and Wong, K Y Kevin and Wong, W S Fred and Peh, Hong Yong},
title = {Resolution of innate immune cells with proresolving lipid mediators in idiopathic pulmonary fibrosis},
journal = {Journal of Leukocyte Biology},
year = {2025},
doi = {10.1093/jleuko/qiaf100}
}
EUVIMED